Results 171 to 180 of about 21,287,561 (278)

Distinct Expression Patterns of VEGFR 1-3 in Gastroenteropancreatic Neuroendocrine Neoplasms: Supporting Clinical Relevance, but not a Prognostic Factor. [PDF]

open access: yesJ Clin Med, 2020
Bösch F   +10 more
europepmc   +1 more source

Combination Therapy With Sintilimab and Anlotinib for Advanced Undifferentiated Pleomorphic Sarcoma: A Case Report and Literature Review

open access: yesClinical Case Reports, Volume 14, Issue 7, July 2026.
ABSTRACT This report describes the case of a 73‐year‐old woman with advanced undifferentiated pleomorphic sarcoma (UPS) who was intolerant to chemotherapy. Following amputation, she received sintilimab plus anlotinib and achieved a partial response with 76.6% tumor reduction.
Yan Chen, Ronghua Chu
wiley   +1 more source

Belzutifan for Metastatic TFE3‐Rearranged Renal Cell Carcinoma With Pulmonary Metastases: A Case Report

open access: yesIJU Case Reports, Volume 9, Issue 4, July 2026.
ABSTRACT Introduction Belzutifan is effective in patients with previously treated advanced clear cell renal cell carcinoma. However, evidence for its use in non‐clear cell renal cell carcinoma remains limited. Case Presentation A 33‐year‐old Japanese woman underwent total nephrectomy for a 10‐cm renal tumor with lung metastases.
Kazutaka Nakamura   +9 more
wiley   +1 more source

Coordinated activation of VEGFR-1 and VEGFR-2 is a potent arteriogenic stimulus leading to enhancement of regional perfusion

open access: yes, 2017
Objective: The process of arteriogenesis is driven by various growth factors including vascular endothelial growth factor (VEGF)-A, which mediates its activity through VEGFR-2 (Flk-1/KDR) on endothelial cells and through VEGFR-1 (Flt-1) on endothelial ...
Wangler, Christoph   +9 more
core  

A Case of Acalculous Cholecystitis During Lenvatinib Plus Pembrolizumab Therapy for Advanced Renal Cell Carcinoma

open access: yesIJU Case Reports, Volume 9, Issue 4, July 2026.
ABSTRACT Introduction Lenvatinib plus pembrolizumab is a standard first‐line therapy for advanced renal cell carcinoma (RCC), and acute acalculous cholecystitis is a rare adverse event. Case Presentation A 60‐year‐old woman with metastatic TFE3‐positive non–clear cell RCC, classified as poor risk by the International Metastatic RCC Database Consortium (
Erika Soga   +9 more
wiley   +1 more source

Constitutive expression of VEGF, VEGFR-1, and VEGFR-2 in normal eyes.

open access: yesInvestigative ophthalmology & visual science, 1999
The expression of vascular endothelial growth factor (VEGF) and its high-affinity receptors VEGFR-1 and VEGFR-2 was investigated in normal eyes.Monkey and rat eyes were surgically removed in animals under deep anesthesia and immediately prepared for study.
I, Kim   +6 more
openaire   +1 more source

VEGFR-2 and VEGFR-3 Expression as a Function of Jagged-1 Over-Expression in HUVEC Cells

open access: yes, 2014
Angiogenesis is the sprouting of new blood vessels from pre-existing vessels initiated from vascular endothelial cells in response to exogenous chemical signals.
Stubbs, Caleb
core  

RNA Modifications in Tumor Microenvironment: A New Dimension for Cancer Treatment

open access: yesMedComm, Volume 7, Issue 7, July 2026.
Tumor initiation and progression depend on a supportive and highly heterogeneous tumor microenvironment (TME). RNA modifications regulate signaling pathways and cytokine networks that shape TME dynamics, facilitating interactions between cancer cells and noncancerous stromal cells, and ultimately promoting immune evasion and tumor progression ...
Qiwen Li   +3 more
wiley   +1 more source

Immunolocalization of VEGF, VEGFR-1 and VEGFR-2 in lung tissues after acute hemorrhage in rats

open access: yes
In treatment of hypovolemia it is important to reestablish normal tissue hemodynamics after fluid resuscitation. Vascular endothelial growth factor (VEGF) and VEGF receptors (VEGFR) have been identified as important in many physiological and pathological,
Ekerbicer, N   +3 more
core  

Home - About - Disclaimer - Privacy